NEW YORK, NY / ACCESSWIRE / March 8, 2018 / U.S. markets slumped Wednesday after Gary Cohn, President Trump's top economic advisor, announced his resignation. The Dow Jones Industrial Average hit a low of 24,535.12, before settling to close at 24,801.36, a decrease of 0.33 percent, while the S&P 500 Index hit a low of 2,701.74, before settling to close at 2,726.80, a decrease of 0.05 percent. The Nasdaq Composite Index touched a low of 7,311.74, before settling to close at 7,396.65, an increase of 0.33 percent.
"It is not so much the resignation, but the role that Cohn has played in the administration. He was seen as the voice of economic stability and a spokesperson for financial markets," said Brad McMillan, chief investment officer for Commonwealth Financial Network, in a note to investors, according to MarketWatch.
RDI Initiates Coverage on:
Celldex Therapeutics, Inc.
Celldex Therapeutics' stock moved 2.49% higher Wednesday, to close the day at $2.47. The stock recorded a trading volume of 1,530,131 shares, which was above its three months average volume of 1,209,913 shares. In the last year, Celldex Therapeutics' shares have traded in a range of 2.20 - 3.75. The stock is currently trading 34.13% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.54 is below its 200-day moving average of $2.72. Shares of Celldex Therapeutics have lost roughly 2.37 percent in the past month and are down 13.03 percent year-to-date.
Access RDI's Celldex Therapeutics, Inc. Research Report at:
On Wednesday, shares of Geron recorded a trading volume of 1,989,789 shares, which was below the three months average volume of 2,364,613 shares. The stock ended the day 5.10% higher at 2.68. The share price has gained 54.02% from its 52-week low with a 52-week trading range of 1.74 - 3.15. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $2.28 is greater than its 200-day moving average of $2.10. Shares of Geron have gained roughly 3.88 percent in the past month and are up 48.89 percent year-to-date.
Access RDI's Geron Corporation Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.